Panbela Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jennifer Simpson
Chief executive officer
US$571.9k
Total compensation
| CEO salary percentage | 92.15% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.0001% |
| Management average tenure | no data |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Panbela Therapeutics dips 24% on pricing $6M public offering
Sep 30Panbela Therapeutics GAAP EPS of -$1.51
Aug 15Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth
Feb 18
Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication
Jan 06Will Panbela Therapeutics (NASDAQ:PBLA) Spend Its Cash Wisely?
Nov 02Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth
Jul 15We Think Panbela Therapeutics (NASDAQ:PBLA) Can Afford To Drive Business Growth
Mar 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$37m |
| Jun 30 2024 | n/a | n/a | -US$38m |
| Mar 31 2024 | n/a | n/a | -US$36m |
| Dec 31 2023 | US$572k | US$527k | -US$34m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$20m |
| Mar 31 2023 | n/a | n/a | -US$36m |
| Dec 31 2022 | US$694k | US$506k | -US$35m |
| Sep 30 2022 | n/a | n/a | -US$34m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$12m |
| Dec 31 2021 | US$1m | US$477k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$2m | US$146k | -US$5m |
Compensation vs Market: Jennifer's total compensation ($USD571.92K) is about average for companies of similar size in the US market ($USD655.68K).
Compensation vs Earnings: Jennifer's compensation has been consistent with company performance over the past year.
CEO
Jennifer Simpson (56 yo)
Dr. Jennifer K. Simpson, Ph.D. M.S.N. C.R.N.P. has been the Chief Executive Officer, President and Director of Panbela Therapeutics, Inc. (formerly known as Sun BioPharma, Inc.) since July 15, 2020. She se...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.8yrs | US$571.92k | 0.00014% $ 1.7 | |
| Vice Chair & Lead Independent Director | 9.7yrs | US$85.14k | 0% $ 0 | |
| Chairman | 9.7yrs | US$76.14k | 0.00045% $ 5.5 | |
| Director | 2.9yrs | US$43.63k | 0.000020% $ 0.2 | |
| Independent Director | 2.9yrs | US$56.13k | 0.00023% $ 2.8 | |
| Independent Director | 5.4yrs | US$52.63k | 0% $ 0 | |
| Independent Director | 9.7yrs | US$61.13k | 0.00045% $ 5.5 | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
Experienced Board: PBLA's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 16:23 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Panbela Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |